FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2003458114> ?p ?o ?g. }

• W2003458114 endingPage "60" @default.
• W2003458114 startingPage "54" @default.
• W2003458114 abstract "This study aims to determine the efficacy and safety of soy isoflavones in controlling the symptoms and signs of lower urinary tract symptoms due to benign prostate hyperplasia (BPH).This was a prospective, randomized, double-blind, placebo-controlled pilot study.This trial was conducted at two hospitals in Hong Kong between May 2006 and September 2007.One hundred and seventy-six (176) participants diagnosed with BPH were recruited from outpatient clinics. Participants with lower urinary tract symptoms were recruited through newspaper and radio interviews, posters placed at government outpatient clinics, and a public seminar offered by the investigators.Participants were randomly assigned to either intervention (40 mg of isoflavones daily from Soylife 40) or placebo groups in a double-blind fashion.The primary outcome parameter of peak urine flow rate and the second outcome parameters of postresidual urine volume, lower urinary tract symptoms, testosterone, prostate-specific antigen, quality of life, diet, and safety profile (liver and renal function) were collected. All parameters were assessed at baseline, 6 months, and 12 months in a 12-month study period except testosterone, prostate-specific antigen, and safety profile, which were assessed at baseline and at 12 months.The peak urine flow rate (Qmax), postresidual urine volume, International Prostate Symptoms Scores (IPSS), and 36-Item Short Form Health Survey (SF-36) significantly improved from baseline to the 12th month within both groups. However, when compared between groups, Qmax (p=0.055) and incomplete emptying subscore in IPSS (p=0.05) were marginally/statistically different between the two groups from the 6th to the 12th months, in addition to the general health domain of SF-36 from the baseline to 12th month (p=0.02) and from the 6th month to the 12th month (p=0.055). Isoflavones were generally safe and well tolerated.This randomized control pilot study showed only slight superiority of isoflavones over placebo over 12 months with otherwise surprising beneficial effects in both groups. Tolerability of isoflavones was excellent; thus it has laid foundations for further studies of isoflavones in BPH with focus on dosage and possible specificity of the effect." @default.
• W2003458114 created "2016-06-24" @default.
• W2003458114 creator A5021895638 @default.
• W2003458114 creator A5033480820 @default.
• W2003458114 creator A5066695904 @default.
• W2003458114 creator A5071558285 @default.
• W2003458114 creator A5071662333 @default.
• W2003458114 creator A5078866682 @default.
• W2003458114 creator A5082538486 @default.
• W2003458114 date "2012-01-01" @default.
• W2003458114 modified "2023-10-16" @default.
• W2003458114 title "Isoflavones in Treating Watchful Waiting Benign Prostate Hyperplasia: A Double-Blinded, Randomized Controlled Trial" @default.
• W2003458114 cites W100997517 @default.
• W2003458114 cites W1575513802 @default.
• W2003458114 cites W1990301115 @default.
• W2003458114 cites W1992689937 @default.
• W2003458114 cites W1994182197 @default.
• W2003458114 cites W2002604544 @default.
• W2003458114 cites W2003712713 @default.
• W2003458114 cites W2014896667 @default.
• W2003458114 cites W2015145074 @default.
• W2003458114 cites W2019050729 @default.
• W2003458114 cites W2024434952 @default.
• W2003458114 cites W2044571026 @default.
• W2003458114 cites W2051185023 @default.
• W2003458114 cites W2059622091 @default.
• W2003458114 cites W2059886775 @default.
• W2003458114 cites W2069285710 @default.
• W2003458114 cites W2076436776 @default.
• W2003458114 cites W2082546704 @default.
• W2003458114 cites W2085557269 @default.
• W2003458114 cites W2097184022 @default.
• W2003458114 cites W2114595149 @default.
• W2003458114 cites W2131032307 @default.
• W2003458114 doi "https://doi.org/10.1089/acm.2010.0077" @default.
• W2003458114 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22268969" @default.
• W2003458114 hasPublicationYear "2012" @default.
• W2003458114 type Work @default.
• W2003458114 sameAs 2003458114 @default.
• W2003458114 citedByCount "23" @default.
• W2003458114 countsByYear W20034581142012 @default.
• W2003458114 countsByYear W20034581142013 @default.
• W2003458114 countsByYear W20034581142014 @default.
• W2003458114 countsByYear W20034581142016 @default.
• W2003458114 countsByYear W20034581142017 @default.
• W2003458114 countsByYear W20034581142019 @default.
• W2003458114 countsByYear W20034581142020 @default.
• W2003458114 countsByYear W20034581142021 @default.
• W2003458114 countsByYear W20034581142022 @default.
• W2003458114 crossrefType "journal-article" @default.
• W2003458114 hasAuthorship W2003458114A5021895638 @default.
• W2003458114 hasAuthorship W2003458114A5033480820 @default.
• W2003458114 hasAuthorship W2003458114A5066695904 @default.
• W2003458114 hasAuthorship W2003458114A5071558285 @default.
• W2003458114 hasAuthorship W2003458114A5071662333 @default.
• W2003458114 hasAuthorship W2003458114A5078866682 @default.
• W2003458114 hasAuthorship W2003458114A5082538486 @default.
• W2003458114 hasBestOaLocation W20034581142 @default.
• W2003458114 hasConcept C121608353 @default.
• W2003458114 hasConcept C126322002 @default.
• W2003458114 hasConcept C126894567 @default.
• W2003458114 hasConcept C142724271 @default.
• W2003458114 hasConcept C168563851 @default.
• W2003458114 hasConcept C204787440 @default.
• W2003458114 hasConcept C27081682 @default.
• W2003458114 hasConcept C2776235491 @default.
• W2003458114 hasConcept C2776547966 @default.
• W2003458114 hasConcept C2779478474 @default.
• W2003458114 hasConcept C2910675164 @default.
• W2003458114 hasConcept C2994223898 @default.
• W2003458114 hasConcept C3020110884 @default.
• W2003458114 hasConcept C71924100 @default.
• W2003458114 hasConceptScore W2003458114C121608353 @default.
• W2003458114 hasConceptScore W2003458114C126322002 @default.
• W2003458114 hasConceptScore W2003458114C126894567 @default.
• W2003458114 hasConceptScore W2003458114C142724271 @default.
• W2003458114 hasConceptScore W2003458114C168563851 @default.
• W2003458114 hasConceptScore W2003458114C204787440 @default.
• W2003458114 hasConceptScore W2003458114C27081682 @default.
• W2003458114 hasConceptScore W2003458114C2776235491 @default.
• W2003458114 hasConceptScore W2003458114C2776547966 @default.
• W2003458114 hasConceptScore W2003458114C2779478474 @default.
• W2003458114 hasConceptScore W2003458114C2910675164 @default.
• W2003458114 hasConceptScore W2003458114C2994223898 @default.
• W2003458114 hasConceptScore W2003458114C3020110884 @default.
• W2003458114 hasConceptScore W2003458114C71924100 @default.
• W2003458114 hasIssue "1" @default.
• W2003458114 hasLocation W20034581141 @default.
• W2003458114 hasLocation W20034581142 @default.
• W2003458114 hasLocation W20034581143 @default.
• W2003458114 hasOpenAccess W2003458114 @default.
• W2003458114 hasPrimaryLocation W20034581141 @default.
• W2003458114 hasRelatedWork W1563460086 @default.
• W2003458114 hasRelatedWork W1962507201 @default.
• W2003458114 hasRelatedWork W2006615433 @default.
• W2003458114 hasRelatedWork W2021270740 @default.
• W2003458114 hasRelatedWork W2033685093 @default.
• W2003458114 hasRelatedWork W2035396100 @default.

• next